PAG
CYTK icon

Private Advisor Group’s Cytokinetics CYTK Stock Holding History

Private Advisor Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-291
Closed -$7K – 1971
2020
Q2 		$7K Buy
+291
New +$5.46K ﹤0.01% 3070

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Private Advisor Group's CYTK Position: Q3 2020 in Review

Private Advisor Group sold out of Cytokinetics (CYTK) in Q3 2020, closing a stake of 291 shares — an estimated $7K sold.

Private Advisor Group first reported a position in CYTK in Q2 2020 and held it in 1 quarter. The position peaked at $7K in Q2 2020. 181 funds tracked by Wall St. Rank hold CYTK as of Q3 2020.

  • Private Advisor Group reported no remaining Cytokinetics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 291 Cytokinetics shares in Q3 2020, an estimated $7K.
  • Private Advisor Group first reported a position in Cytokinetics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Cytokinetics position peaked at $7K in Q2 2020.
  • 181 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.